| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/27/2026 | ±3.0% | -0.6% | over-priced |
| 06/02/2026 | ±3.1% | -1.2% | over-priced |
| 08/28/2025 | ±1.9% | -0.6% | over-priced |
| 05/29/2025 | ±2.5% | +1.1% | over-priced |
| 12/05/2024 | ±3.4% | -1.7% | over-priced |
| 08/29/2024 | ±2.4% | +0.2% | over-priced |
| 11/30/2023 | ±1.7% | +1.4% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2027 | $6.55 | $3.0B | $282M |
| Q1 FY2027 | $7.74 | $3.2B | $340M |
| Q4 FY2026 | — | $0 | $0 |
| Q2 FY2026 | $5.78 | $2.8B | $261M |
Ulta Beauty, Inc. Common Stock (ULTA) reports in 142 days, with the next report estimated for 02/01/2027. Across the last 7 reports, options priced an average ±2.5% earnings move while the stock actually moved 1.0% on average — the market has systematically over-priced ULTA's earnings risk. Fundamentals into the print: EPS down 2.2% year-over-year, revenue up 6.6%. QuantLogix's live 5-factor engine currently reads ULTA as a neutral at 45/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →